Canntab Has Experienced Significant Growth

In a recent segment of MidasLetter Live, Canntab Therapeutics (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein spoke to Midas about the work the company has done in recent months to double the company’s valuation.

During the segment, Renwick and Goldstein provided an overview of what Canntab does, which is to transform cannabis resins into hard tablet/pill form. The company is developing these products as they await for Health Canada approval of hard tablets as a viable form of oral consumption of cannabis. To Canntab, the value of hard tablets is that they protect cannabinoids from degradation as they pass through the digestive system. They also offer a more stable delivery method.

In terms of revenue, Canntab is generating licensing fees from their deal with Emblem (TSXV:EMC,OTCQX:EMMBF), a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada. Under the licensing agreement, Emblem has agreed to develop and market three of Canntab’s products. Canntab also expects to conduct its first product sales in 2019.

The company is focused on developing both THC and CBD products. For the latter, Goldstein emphasized the importance of using full-spectrum CBD oils, which will now be available following legalization. Full-spectrum CBD can be extracted from the hemp plant. Up until now, hemp oil could only be extracted from the hemp seed, which does not have as much CBD value. Canntab plans to encapsulate full-spectrum CBD oil into tablets and market that product, serving the medical market particularly.

The Canntab executives emphasized that despite the potential innovations on the horizon for cultivating cannabinoids, whether it be through the cannabis plant or in the laboratory, there will always be a need for effective delivery methods, and that is what Canntab can provide.

To watch the full interview, click here.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation.